First patient in CytoDyn PRO 140 study reaches two years of complete virologic suppression

CytoDyn Inc., a company specializing in biotechnology that is dedicated to the development of new antibody therapies for the treatment of human immunodeficiency virus (HIV), recently announced that the first of 11 patients with HIV-1 in its Phase 2b extension study of PRO 140 has achieved two years of complete virologic suppression.

There are four other patients involved in the study that are expected to reach the same two-year mark in the next three weeks. Five other patients will also reach the milestone within the next two months.

“We are pleased that 10 HIV patients who participated in our Phase 2b study are approaching the significant milestone of two years of complete virologic suppression on PRO 140 as a single agent,” CytoDyn’s President and CEO Nader Pourhassan said.  “These patients are receiving weekly subcutaneous PRO 140 injections as a substitution for daily regiments of Highly Active Antiretroviral Therapy (HAART) regimens without the notable drawbacks of HAART.”

Patients who are currently taking part in the Phase 2b trial have shown full HIV viral load suppression during the 12-week study, during which they received subcutaneous injections or PRO 140 each week in one 350 mg dose.